PDCD1 and non-small cell lung carcinoma: Compared with patients who did not benefit from clinical practice, there was a significant enrichment of Bifidobacterium, Escherichia, and Sarterella in the intestinal flora of patients with clinical benefit, which could predict NSCLC patients receiving anti‐PD‐1 Efficacy of treatment combined with chemotherapy.